LB Pharmaceuticals Inc Developing Novel Therapies for Neuropsychiatric Disorders March 2026 1 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Ex ...

Summary of LB Pharmaceuticals FY Conference Call Company Overview - **Company**: LB Pharmaceuticals (NasdaqGM:LBRX) - **Focus**: Development of LB-102, an antipsychotic drug targeting schizophrenia and bipolar depression Key Points Industry Context - The conference took place during the Piper Sandler Healthcare Conference, highlighting the biotech industry's challenges and opportunities in a tough market [1][2][3] Financial and Operational Highlights - LB Pharmaceuticals successfully completed its IPO, raising approximately **$300 million**, providing sufficient capital to initiate phase 3 studies [41] - The company is well-capitalized to fund both schizophrenia and bipolar depression trials, with a cash runway extending into the **second quarter of 2028** [41] Clinical Development Plans - **Phase 3 Study for Schizophrenia**: - Target initiation in **Q1 2026** [5] - Sample size increased from **400 to 460** to enhance statistical power from **80% to 85%** [8][9] - Expected to announce top-line data in the **first half of 2027** [9][16] - **Phase 2 Study for Bipolar Depression**: - Planned to start in **Q1 2026** with a two-arm trial design [37] - Doses will be **25 mg and 50 mg**, with a total of **320 patients** targeted [38] Drug Differentiation and Market Positioning - **LB-102** is a modified version of **Amisulpride**, designed to improve blood-brain barrier permeability and allow for once-daily dosing [21][22] - LB-102 shows competitive efficacy and a potentially best-in-class safety profile, with a low rate of extrapyramidal symptoms (EPS) observed in trials [24][25] - The drug aims to address unmet needs in cognition and negative symptoms associated with schizophrenia [26][27] Regulatory Considerations - The company has received confirmation from the FDA that the phase 2 trial was designed to be registrational in quality, potentially allowing for a streamlined approval process with just one successful phase 3 trial [17][18] Market Opportunity - Amisulpride has been widely used in Europe but has never been approved in the U.S. due to historical regulatory challenges [29][30] - LB-102 is positioned to fill this gap, with the potential to become a preferred branded therapeutic in the antipsychotic market [24] Future Developments - The company is exploring the development of a long-acting injectable formulation for LB-102, aiming for a subcutaneous once-monthly option [40] - The focus will be on maintaining a low EPS rate while evaluating both schizophrenia and bipolar depression dosing paradigms [39] Investor Sentiment - The successful IPO and subsequent stock performance have been positively received, indicating strong investor confidence in LB Pharmaceuticals' future prospects [42][45] Additional Insights - The company emphasized the importance of managing placebo rates in clinical trials, utilizing multiple vendors to identify professional patients [32][33] - The differentiation of LB-102 from existing treatments is based on its unique pharmacological profile and dosing regimen, which may enhance patient compliance and treatment outcomes [22][24]

Summary of LB Pharmaceuticals Conference Call Company Overview - **Company**: LB Pharmaceuticals (NasdaqGM:LBRX) - **Founded**: 2015 - **Focus**: Developing a novel antipsychotic (LB102) for schizophrenia and mood disorders, aiming to improve blood-brain barrier penetration and potency compared to Amisulpride [3][4] Key Points Clinical Development - **Phase Two Trial for Schizophrenia**: - Enrolled 359 patients, designed to be registrational [6] - Demonstrated statistically significant efficacy with a clinically meaningful reduction in PANSS total score [6] - Safety profile shows a low rate of extrapyramidal symptoms (EPS): 0.9% at 50 mg and 5.6% at 100 mg [14] - **Phase Three Trial Plans**: - Targeting 460 patients across 25 sites, with a duration of six weeks [7][11] - Aims to maintain a similar design to the phase two trial to manage placebo rates [10] - Increased sample size to enhance statistical power to 85% [11] Safety and Efficacy - **Differentiation in Safety**: - LB102 is expected to have a class-leading safety profile, particularly in EPS rates compared to competitors like Vraylar [14] - **Cognitive Effects**: - Significant treatment effect on cognition observed, with a robust dose-dependent effect [19] - Plans to further investigate cognition and negative symptoms in future trials [21] Expansion into Bipolar Depression - **Rationale for Bipolar Indication**: - LB102's mechanism supports both psychosis-related and depression-related indications [23] - Utilizes safety data from schizophrenia trials to streamline approval for bipolar depression [23] - Historical data from Amisulpride supports the efficacy in mood disorders [24][26] Future Development Plans - **Potential for Major Depressive Disorder (MDD)**: - LB Pharmaceuticals is considering MDD as a future indication due to its larger patient population and revenue potential [47][49] - **Exploration of Negative Symptoms**: - Plans to conduct studies focusing on negative symptoms in stable patients [52] Financial Position - **IPO and Funding**: - Completed an IPO raising approximately $300 million, funding phase three schizophrenia trial and phase two bipolar depression trial [58] Timelines - **Expected Data Readouts**: - Schizophrenia trial data anticipated in the second half of 2027 [45] - Bipolar depression trial data expected in the first quarter of 2028 [45] Additional Insights - **Engagement with FDA**: - Positive interactions with the FDA regarding the approval process for schizophrenia with just one successful phase three trial [4] - **Real-World Use of Amisulpride**: - Over 2 million prescriptions for Amisulpride in Europe in 2024, indicating its continued relevance and safety profile [17] This summary encapsulates the critical aspects of LB Pharmaceuticals' conference call, highlighting the company's strategic direction, clinical trial progress, and financial health.